NSE List Price : ₹

subscription

Category	Times
QIBs	15.94x
HNIs	0.39x
Retail	1.42x
Total : 1.06x

IPO Market Lot(s) Distribution

Application	Lot Size	Shares	Amount
Retail Minimum	2	2,000	₹278,000
Retail Maximum	2	2,000	₹278,000
S-HNI Minimum	3	3,000	₹417,000
S-HNI Maximum	7	7,000	₹973,000
B-HNI Minimum	8	8,000	₹1,112,000

About the Company

Bio Medica Laboratories is among the prominent manufacturers of parenteral medicines (injectable formulations) in India. The company is engaged in the development of a diverse portfolio of injectable products catering to both human and veterinary healthcare requirements. It manufactures generic medicines in the form of liquid injections and dry powder injections, available in different packaging formats such as ampoules and vials.

The company also emphasizes delivering safe and high-quality products while adhering to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). Over the years, it has established a strong reputation for offering dependable and effective healthcare solutions. Its product portfolio includes injectables for the domestic market, export-oriented injectables, and veterinary injectables.

Company Financial Report

_{Amount ₹ in Crores}

Period Ended	Revenue	Expense	PAT	Assets
2023	₹16.25	₹15.80	₹0.33	₹17.57
2024	₹15.34	₹11.69	₹2.50	₹19.53
2025	₹38.33	₹25.18	₹9.79	₹39.12
Nov 2025	₹28.63	₹16.95	₹8.66	₹65.17

Company Promoter

Mr. Mukesh Mehta

Mr. Pradeep Mehta

Know before investing

• • Strengths

  Wide-ranging injectable product portfolio: The company provides an extensive range of liquid and dry powder injectable products designed to meet diverse therapeutic and healthcare needs.

  Skilled promoters and experienced workforce: The management and operational teams have strong industry expertise, enabling efficient manufacturing operations and maintenance of quality standards.

• • Risks

  Regulatory non-compliance risk: Earlier suspension of operations at one of the manufacturing facilities due to non-compliance with regulatory requirements may adversely affect the company’s operations and reputation.

  Manufacturing and quality assurance risk: Any defects in production or product quality concerns could result in regulatory penalties, legal claims, and damage to the company’s reputation.

Objects of the Issue & Utilisation of proceeds

Repayment of Loan.

Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises.

General Corporate Purpose.

Company  Address

Bio Medica Laboratories Ltd.
Plot No. 11B-11C, Sector-E, Sanwer Road
Industrial Area, Industrial Estate (Indore),
Indore, Madhya Pradesh, 452015
Phone: +91 7314102751
Email: companysecretary@biomedica.co.in
Website: http://www.biomedica.co.in/

IPO Registrar

Skyline Financial Services Pvt.Ltd.
Phone: 02228511022
Email: ipo@skylinerta.com
Website: https://www.skylinerta.com/ipo.php

IPO Review

Avoid